Cancer Causes & Control

, Volume 24, Issue 11, pp 1947–1954 | Cite as

Coffee and tea consumption in relation to prostate cancer prognosis

  • Milan S. Geybels
  • Marian L. Neuhouser
  • Jonathan L. Wright
  • Marni Stott-Miller
  • Janet L. Stanford
Original Paper

Abstract

Background

Bioactive compounds found in coffee and tea may delay the progression of prostate cancer.

Methods

We investigated associations of pre-diagnostic coffee and tea consumption with risk of prostate cancer recurrence/progression. Study participants were men diagnosed with prostate cancer in 2002–2005 in King County, Washington, USA. We assessed the usual pattern of coffee and tea consumption two years before diagnosis date. Prostate cancer-specific outcome events were identified using a detailed follow-up survey. Multivariable Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95 % confidence intervals (CIs).

Results

The analysis of coffee intake in relation to prostate cancer recurrence/progression included 630 patients with a median follow-up of 6.4 years, during which 140 prostate cancer recurrence/progression events were recorded. Approximately 61 % of patients consumed at least one cup of coffee per day. Coffee consumption was associated with a reduced risk of prostate cancer recurrence/progression; the adjusted HR for ≥4 cups/day versus ≤1 cup/week was 0.41 (95 % CI: 0.20, 0.81; p for trend = 0.01). Approximately 14 % of patients consumed one or more cups of tea per day, and tea consumption was unrelated to prostate cancer recurrence/progression.

Conclusion

Results indicate that higher pre-diagnostic coffee consumption is associated with a lower risk of prostate cancer recurrence/progression. This finding will require replication in larger studies.

Keywords

Prostate cancer Progression Biochemical recurrence Mortality Coffee Tea 

References

  1. 1.
    Wilson KM, Kasperzyk JL, Rider JR et al (2011) Coffee consumption and prostate cancer risk and progression in the health professionals follow-up study. J Natl Cancer Inst 103:876–884PubMedCrossRefGoogle Scholar
  2. 2.
    Arab L (2010) Epidemiologic evidence on coffee and cancer. Nutr Cancer 62:271–283PubMedCrossRefGoogle Scholar
  3. 3.
    Farah A, Monteiro M, Donangelo CM, Lafay S (2008) Chlorogenic acids from green coffee extract are highly bioavailable in humans. J Nutr 138:2309–2315PubMedCrossRefGoogle Scholar
  4. 4.
    Higdon JV, Frei B (2006) Coffee and health: a review of recent human research. Crit Rev Food Sci Nutr 46:101–123PubMedCrossRefGoogle Scholar
  5. 5.
    Nkondjock A (2009) Coffee consumption and the risk of cancer: an overview. Cancer Lett 277:121–125PubMedCrossRefGoogle Scholar
  6. 6.
    Yang H, Rouse J, Lukes L et al (2004) Caffeine suppresses metastasis in a transgenic mouse model: a prototype molecule for prophylaxis of metastasis. Clin Exp Metastasis 21:719–735PubMedCrossRefGoogle Scholar
  7. 7.
    Higdon JV, Frei B (2003) Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 43:89–143PubMedCrossRefGoogle Scholar
  8. 8.
    Yang CS, Wang H, Li GX, Yang Z, Guan F, Jin H (2011) Cancer prevention by tea: evidence from laboratory studies. Pharmacol Res 64:113–122PubMedCrossRefGoogle Scholar
  9. 9.
    Connors SK, Chornokur G, Kumar NB (2012) New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. Nutr Cancer 64:4–22PubMedCrossRefGoogle Scholar
  10. 10.
    Henning SM, Wang P, Heber D (2011) Chemopreventive effects of tea in prostate cancer: green tea versus black tea. Mol Nutr Food Res 55:905–920PubMedCrossRefGoogle Scholar
  11. 11.
    Johnson JJ, Bailey HH, Mukhtar H (2010) Green tea polyphenols for prostate cancer chemoprevention: a translational perspective. Phytomedicine 17:3–13PubMedCrossRefGoogle Scholar
  12. 12.
    Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL (2008) Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 168:250–260PubMedCrossRefGoogle Scholar
  13. 13.
    Patterson RE, Kristal AR, Tinker LF, Carter RA, Bolton MP, Agurs-Collins T (1999) Measurement characteristics of the women’s health initiative food frequency questionnaire. Ann Epidemiol 9:178–187PubMedCrossRefGoogle Scholar
  14. 14.
    Yuan JM, Sun C, Butler LM (2011) Tea and cancer prevention: epidemiological studies. Pharmacol Res 64:123–135PubMedCrossRefGoogle Scholar
  15. 15.
    Roach M 3rd, Hanks G, Thames H Jr et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974PubMedCrossRefGoogle Scholar
  16. 16.
    Wright JL, Kwon EM, Lin DW et al (2010) CYP17 polymorphisms and prostate cancer outcomes. Prostate 70:1094–1101PubMedCrossRefGoogle Scholar
  17. 17.
    Grambsch PM, Therneau TM (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515–526CrossRefGoogle Scholar
  18. 18.
    Denham JW, Steigler A, Wilcox C et al (2009) Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival? Cancer 115:4477–4487PubMedCrossRefGoogle Scholar
  19. 19.
    Arab L, Su LJ, Steck SE et al (2012) Coffee consumption and prostate cancer aggressiveness among African and Caucasian Americans in a population-based study. Nutr Cancer 64:637–642PubMedCrossRefGoogle Scholar
  20. 20.
    Geybels MS, Neuhouser ML, Stanford JL. (2012) Associations of tea and coffee consumption with prostate cancer risk. Cancer causes & control: CCC (accepted)Google Scholar
  21. 21.
    Shafique K, McLoone P, Qureshi K, Leung H, Hart C, Morrison DS (2012) Coffee consumption and prostate cancer risk: further evidence for inverse relationship. Nutr J 11:42PubMedCrossRefGoogle Scholar
  22. 22.
    Klotz L (2012) Active surveillance: the canadian experience with an “inclusive approach”. J Natl Cancer Inst Monogr 2012:234–241PubMedCrossRefGoogle Scholar
  23. 23.
    Freedman ND, Park Y, Abnet CC, Hollenbeck AR, Sinha R (2012) Association of coffee drinking with total and cause-specific mortality. N Engl J Med 366:1891–1904PubMedCrossRefGoogle Scholar
  24. 24.
    Hashimoto T, He Z, Ma WY et al (2004) Caffeine inhibits cell proliferation by G0/G1 phase arrest in JB6 cells. Cancer Res 64:3344–3349PubMedCrossRefGoogle Scholar
  25. 25.
    He Z, Ma WY, Hashimoto T, Bode AM, Yang CS, Dong Z (2003) Induction of apoptosis by caffeine is mediated by the p53, Bax, and caspase 3 pathways. Cancer Res 63:4396–4401PubMedGoogle Scholar
  26. 26.
    Song F, Qureshi AA, Han J (2012) Increased caffeine intake is associated with reduced risk of basal cell carcinoma of the skin. Cancer Res 72:3282–3289PubMedCrossRefGoogle Scholar
  27. 27.
    Holick CN, Smith SG, Giovannucci E, Michaud DS (2010) Coffee, tea, caffeine intake, and risk of adult glioma in three prospective cohort studies. Cancer Epidemiol Biomarkers Prev 19:39–47PubMedCrossRefGoogle Scholar
  28. 28.
    Tworoger SS, Gertig DM, Gates MA, Hecht JL, Hankinson SE (2008) Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer. Cancer 112:1169–1177PubMedCrossRefGoogle Scholar
  29. 29.
    Huber WW, Rossmanith W, Grusch M et al (2008) Effects of coffee and its chemopreventive components kahweol and cafestol on cytochrome P450 and sulfotransferase in rat liver. Food Chem Toxicol 46:1230–1238PubMedCrossRefGoogle Scholar
  30. 30.
    Tunnicliffe JM, Shearer J (2008) Coffee, glucose homeostasis, and insulin resistance: physiological mechanisms and mediators. Appl Physiol Nutr Metab 33:1290–1300PubMedCrossRefGoogle Scholar
  31. 31.
    Lee WJ, Zhu BT (2006) Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis 27:269–277PubMedCrossRefGoogle Scholar
  32. 32.
    Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A (2006) Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 66:1234–1240PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Milan S. Geybels
    • 1
  • Marian L. Neuhouser
    • 2
    • 3
  • Jonathan L. Wright
    • 2
    • 4
  • Marni Stott-Miller
    • 2
  • Janet L. Stanford
    • 2
    • 3
  1. 1.Department of Epidemiology, GROW School for Oncology and Developmental BiologyMaastricht UniversityMaastrichtThe Netherlands
  2. 2.Division of Public Health SciencesFred Hutchinson Cancer Research Center, SeattleSeattleUS
  3. 3.Department of Epidemiology, School of Public HealthUniversity of WashingtonSeattleUS
  4. 4.Department of Urology, School of MedicineUniversity of WashingtonSeattleUS

Personalised recommendations